書籍詳細

炎症リウマチ

P.9 掲載の参考文献

• 1) Bohan A, Peter JB:Polymyositis and dematomyositis (First of two parts). N Engl J Med 292:344, 1975

• 2) Dalakas MC:Immunopathpgenesis of Inflammatory Myopathies. Ann Neurol 37:S74-S86, 1995
  pubmed

• 3) Calabrese LH, Chou SM:Inclusion body myositis. Rheum Dis Clin N America 20:955-972, 1994

• 4) Chou SM:Myxovirus-like structures in a case of human chronic polymyositis. Science 158:1753, 1967

• 5) Yunis ET, Samaha FJ:Inclusion body myositis. Lab invest 25:240, 1971. Papo T:Macrophagic myofasciitis:focal or systemic?. Joint Bone Spine 70:242-245, 2003

• 6) Badrising UA, Maat-Schieman M, van Duinen SG, et al:Epidemiology of inclusion body myositis in the Netherlands:a nationwide study. Neurology 55:1385-1387, 2000

• 7) Bronner IM, van der Meulen MFG, Hoogendijk JE, et al:Polymyositis:a disease entity disputed. Neurology 58:A389, 2002

• 8) Kissel JT:Misunderstandings, misperceptions, and mistakes in the management of the inflammatory myopathies. Sem Neurol 22:41-51, 2002

• 9) Adams EM, Chow CK, Premkumar A, et al:The idiopathic inflammatory myopathies:spectrum of MR imaging findings. Radiographics 15:563-574, 1995
  pubmed

• 10) Gherardi RK, Conquet M, Cherin P, et al:Macrophagic myofasciitis:an emerging entity. Lancet 352:347-352, 1998

• 11) 前田恵治:新しい炎症性ミオパチー-macrophagic myofasciitis-. リウマチ病セミナーXI (七川歓二監修), pp8-13, 大阪, 永井書店, 2000

• 12) Gherardi RK, Coquet M, Cherin P, et al:Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124:1821-1831, 2001
  pubmed

• 13) Papo T:Macrophagic myofasciitis:focal or systemic? Joint Bone Spine 70:242-245, 2003

• 14) Wiesinger GF, Quittan M, Aringer M, et al:Improvement of physical fitness and muscle strength inpolymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 37:196200, 1998

• 15) Biviji AA, Paiement D, Steinbath LS:Musculoskeletal manifestation of human immunodeficiency virus infection. J Am Acad Orthop Surg 10:312-320, 2002

P.18 掲載の参考文献

• 1) Castleman B, Iverson L, Menendes VP:Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 9:822, 1956

• 2) Keller AR, Hochholzer L, Castlelnan B:Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670, 1972

• 3) Gaba AR, Stein RS, Sweet DI. et al:Multicentric giant lymph node hyperplasia. Am J Clin Pathol 69:86, 1978
  pubmed

• 4) Peterson BA, Grizzera G:Multicentric Castleman's disease. Semin Oncol 20:636, 1993

• 5) Yoshizaki K Matsuda T, Nishimoto N, et al:Pathogenic significance of interleukin-6 (IL-6・BSF-2) in Castleman's disease. Blood 74:1360, 1989

• 6) Sato K, Tsuchiya M, Saldanha J, et al:Reshaping a human antibody to inhibit the interleukin6-dependent tumor cell growth. Cancer Res 53:851, 1993

• 7) Nishimoto N, Sasai M, Shima Y, et al:Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56, 2000
  pubmed

P.25 掲載の参考文献

• 1) Petty RE, Southwood TR, Baum J, et al:Revision of the proposed classification criteria for juvenile idiopathic arthritis. Durban 1997. J Rheumatol 25:1991-1994, 1998
  pubmed

• 2) Fanntini F:Classification of chronic arthritides of childhood (juvenile idiopathic arthritis):criticisms and suggestion to improve the efficacy of the Santigo-Durban criteria. J Rheumatol 28:456-459, 2001

• 3) Manners P, Lesslie J, Speldewinde D, et al:Classification of juvenile idiopathic arthritis:Should family history be include in the criteria. J Rheumatol 30:857-1863, 2003

• 4) Zak M & Pedesia FK:Juvenile chronic arthritis into adulthood:a long-term follow-up study. Rheumatology 39:198-204, 2000

• 5) Lomater C, Gerloni V, Gattinara M, et al:Systemic onset juvenile idiopathic arthritis:a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 39:491-496, 2000

• 6) Minden K, Niewerth M, Listing J, et al:Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 46:2392-2401, 2002
  pubmed

• 7) 0en K, Malleson PN, Cabral DA, et al:Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 29:1989-1999, 2002

• 8)Agl LMA, Rosenkratz M, Lehhmar TLA:Novel therapies for the treatment of juvenile rheumatoid arthritis (JIA). Expert Opin Investig Drugs 12:19-28, 2003

• 9) Woulfraat NM, Kries W:Treatment of refractory juvenile idiopathic arthritis J Rheumatol 28:929-931, 2001

• 10) Rose ES, Ferrandez M, Kiss M, et al:Steady-state plasma concentrations of rofecoxib in children (age 2-5 years) with juvenile rheumatoid arthritis (JRA). Arthritis Rheum 44:S291, 2001

• 11) Cummins R, Wagner-Weiner l, Paaller A:Pseudoporphyria in a patient with juvenile rheumatoid arthritis. J Rheumattol 27:2938-2940, 2000

• 12) Wolf G, Porth J, Staahl RA:Acute renal failure associated with rofecoxib. Ann Inter Med 133:395, 2000

• 13) Gianinid EH, Brewer RI, Kuzmina N, et al:Methotrexate in the treatment of juvenile rheumatoid arthritis:result of the USA-USSR double blind, placebo-controlled trial. N Engl J Med 326:1043-1049, 1992

• 14) Ravelli A, Martini A:Methotrexate in juvenile idiopathic arthritis:ansers and questions. J Rheumatol 27:1830-1833, 2000

• 15) Laahdcnne P, Rapola J, Ylijioki H, et al:Hepatotoxity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy. J Rheumatol 29:2442-2445, 2002

• 16) Ruperto W, Murrey K, Geroni V, et al:Arandomized trial of methotrexate (MTX) in median versus high dosis in children with juvenile idiopathic arthritis (JLA) who failed on standard dose. Arthritis Rheum 45:440, 2002

• 17) Silverman E, Spiegel L, Hawkins D, et al:An initial evaluation of the efficacy and safety of leflonomide and methotrexate in children with polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum 44:S272, 2001

• 18) Spencer CH, Hickey K:The short term safety and efficacy of mycophenolate (Cellcept) in treatment of children with rheumatic diseases. Arthritis Rheum 42:S184, 1999

• 19) Kietz DA, Pepmuller PH, Moore TJ, et al:Clinical response to etanercept in polyarticular course juvenile rheumatoid erthritis. J Rheumatol 28:360-368, 2001

• 20) Lovell DJ, Giannini EH, Reiffa A, et al:Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763-769, 2000

• 21) Kietz DA, Pepmuller PH, Moore TL, et al:Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over two years period. Ann Rheum Dis 61:171-173, 2002
  pubmed

• 22) Takei S, Grou D, Bernstein B, et al:Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol 28:1677-1680, 2001

• 23) Kirnura Y, Li S, Ebner L, et al:Treatment of systemic JIA with etanercept:result of a survey. Arthritis Rheum 43:S257, 2000

• 24) Rohman D, Smith K, Kimura S:Safety and efficacy of etanercept (enbrel) in children with JRA less than 4years of age. Arthritis Rheum 44:S292, 2001

• 25) Higgins GC, Jones K, Rennebohm RM:Variable response of systemic juvenile rheumatoid arthritis to etanercept. Arthritis Rheum 43:S257, 2000

• 26) Gerloni V, Pontikaki I, Desiaati F, et al:Infliximab in the treatment of persistently active refractory juvenile idiopathic (chronic) arthritis:a short-term pilot study. Arthritis Rheum 43:S256, 2000

• 27) Lahdenne P, Honkanen V:Infliximab versus etanercept in the treatment of severe juvenile chronic arthritis. Arthritis Rheum 44:S381, 2000

• 28)Kimura Y, Imundo LF, Li SC:High dose infliximab in the treatment of resistant systelnic juvenile rheumatoid arthritis. Arthritis Rheum 44:S272, 2001

• 29) Elliot MJ, Woo P, Charles P, et al:Suppresion of fever and acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumore necrosis factor-alpha (cA 2). Br J Rheumatol 36:589-593, 1997

• 30) Schmeling H, Mathony K, John V, et al:A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis. a pilot study. Ann Rheum Dis 60:410-412, 2001

• 31) Andrias R, Porras O, Rudge S, et al:Preliminary data from a study of Kineret (anakinra) in children with juvenile rheumatoid arthritis. Arthritis Rheum 45:496, 2002

• 32) Yokota S, Miyamae T, Imagawa T, et al:Therapeutic efficacy of humanized anti-IL-6 receptor anti-body in systemic juvenile idiopathic arthritis. Arthritis rheum 44:S291, 2001

• 33) Sundei RP, Wa.age CA, Zurakowski D:Pilot trial of interferon-β-1a (Avonex) in JRA. Arthritis Rheum 44:S272, 2001

• 34) Coootoc, VarelaG, HernandezV, et al:Use of recombinant interferon gammas in pediatric patients with advanced juvenile rheumatoid arthritis. Biotherapy 11:15-20, 1999

• 35) Wulffrat NM, Brinkmand D, Prieur A, et al:Autologous stem-cell transplantation for refractory juvenile idiopathic arthritis. Arthritis Rheum 43:S381

• 36) Kieer I, Brinkman D, Ten Carter, et al:18 chilllddren after autologous stem cell transplantation for refractory idiopathic arthritis:1 to 51 months of follow-up. Arthritis Rheum 44:S273, 2001

• 37) Wulfraat NM, Kuis W:Treatment of refractory juvenile idiopathic arthritis. J Rheumatol 28:929-931, 2001

• 38) Lehman TJ, Striecel KH, Onel KB:Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr 140:125-127, 2002

• 39) 若年性特発性JIAの難治性病態と治療戦略. 日本リウマチ学会シンポジウム, 東京, 日本リウマチ学会, 2003

骨関節, 脊椎, 神経

P.33 掲載の参考文献

• 1) 勝又 隆:骨疾患とBisphosphonate. リウマチ病セミナーVII (七川歓次監修), pp187-195, 大阪, 永井書店, 1996

• 2) Tsukii K, Shima N, Mochizuki S, et al:esteoclast differentiation factor mediates an essential signal for bone resorption induced by l alpha, 25-dihydroxyvitamin D3, prostaglandin E2, 0r parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 246:337-341, 1998

• 3) Udagawa N, Takahashi N, Jimi E, et al:Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor:receptor activator of NF-kappa B ligand. Bone 25:517-523, 1999
  pubmed

• 4) 0no K, Akatsu T, Murakami T, et al:Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 17:774-781, 2002

• 5) Yoneda T, Sasaki A, Dunstan C, et al:Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99:2509-2517, 1997
  pubmed

• 6) Powell GJ, Southby J, Danks JA, et al:Localization of parathyroid hormone-related protein in breast cancer metastases:increased incidence in bone compared with other sites. Cancer Res 51:3059-3061, 1991
  pubmed

• 7) Guise TA, Yin JJ, Taylor SD, et al:Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544-1549, 1996
  pubmed

• 8) Yin JJ, Selander K, Chirgwin JM, et al:TGF-beta signaling blockade inhibits PTHrP secretion by breastcancer cells and bone metastases development. J Clin Invest 103:197-206, 1999

• 9) Frith JC, Monkkonen J, Blackburn GM, et al:Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5',(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358-1367, 1997
  pubmed

• 10) Rogers MJ, Brown RJ, Hodkin V, et al:Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 224:863-869, 1996
  pubmed

• 11) Luckman SP, Hughes DE, Coxon FP, et al:Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins including Ras. J Bone Miner Res 13:581-589, 1998

• 12) Fisher JE, Rogers MJ, Halasy JM, et al:Alendronate mechanism of action:geranylgeraniol, an intermediate in the mevalonate pathway prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 96:133-138, 1999
  pubmed

• 13) van beek E, Lowik C, van der Pluijm G, et al:The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro:A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14:722-729, 1999

• 14) Fisher JE, Rodan GA, Reszka AA:In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141:4793-4796, 2000
  pubmed

• 15) Coxon FP, Helfrich MH, Van't Hof R, et al:Protein geranylgeranylation is required for osteoclast formation, function, and survival:inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467-1476, 2000
  pubmed

• 16) Pollard M, Luckert PH:The beneficial effects of diphosphonate and piroxicam on the osteolytic and metastatic spread of rat prostate carcinoma cells. Prostate 8:81-86, 1986
  pubmed

• 17) Shevrin DH, Gorny KI, Rosol TJ, et al:Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC-3. Prostate 19:149-154, 1991

• 18) Sasaki A, Boyce BF, Story B, et al:Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557, 1995
  pubmed

• 19) Stearns ME, Wang M:Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 16:116-131, 1996

• 20) Tamura H, Ishii S, Ikeda T, et al:Therapeutic efficacy of pamidronate in combination with chemotherapy tobone metastasis of breast cancer in a rat model. Surg Oncol 5:141-147, 1996

• 21) Sasaki A, Kitamura K, Alcalde RE, et al:Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer 77:279-285, 1998
  pubmed

• 22) Hiraga T, Williams PJ, Mundy GR, et al:The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61:4418-4424, 2001
  pubmed

• 23) Peyruchaud O, Winding B, Pecheur I, et al:Early detection of bone metastases in a murine model using fluorescent human breast cancer cells:application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 16:2027-2034, 2001

• 24) Andela VB, Rosenblatt JD, Schwarz EM, et al:Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis. Clin Orthop 397:228-239, 2002
  pubmed

• 25) Michigami T, Hiraga T, Williams PJ, et al:The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 75:249-258, 2002
  pubmed

• 26) Zhang H, Yano S, Miki T, et al:A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice. Clin Exp Metastasis 20:153-159, 2003
  pubmed

• 27) Sohara Y, Shimada H, Scadeng M, et al:Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. Cancer Res 63:3026-3031, 2003
  pubmed

• 28)Hiraga T, Ueda A, Tamura D, et al:Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 106:973-979, 2003
  pubmed

• 29) Shipman CM, Rogers MJ, Apperley JF, et al:Bisphosphonates induce apoptosis in human myeloma cell lines:a novel anti-tumour activity. Br J Haematol 98:665-672, 1997
  pubmed

• 30) Shipman CM, Croucher PI, Russell RGG, et al:The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58:5294-5297, 1998

• 31) Nishida S, Kikuichi S, Haga H, et al:Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines. Biol Pharm Bull 26:96-100, 2003
  pubmed

• 32) Senaratne SG, Pirianov G, Mansi JL, et al:Bisphosphonates induce apoptosis in human breast cancer cells. Br J Cancer 82:1459-1468, 2000
  pubmed

• 33) Fromigue O, Lagneaux L, Body JJ:Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15:2211-2221, 2000
  pubmed

• 34) Lee MV, Fong EM, Singer FR, et al:Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61:2602-2608, 2001
  pubmed

• 35) 0ades GM, Senaratne SG, Clarke IA, et al:Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170:246-252, 2003

• 36) Jagdev SP, Coleman RE, Shipman CM, et al:The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells:evidence for synergy with paclitaxel. Br J Cancer 84:1126-1134, 2001
  pubmed

• 37) Jagdev SP, Croucher PI, Coleman RE:Zoledronate acid induces apoptosis of breast cancer cells in vitro evidence for additive and synergistic effects with taxol and tamoxifen. Proc Am Soc Clin Oncol 19:664a, 2000

• 38) Tassone P, Forciniti S, Galea E, et al:Growth inhibition and synergistic induction of apoptosis by zoledronateand dexamethasone in human myeloma cell lines. Leukemia 14:841-844, 2000
  pubmed

• 39) van der Pluijm G, Vloedgraven H, van Beek E, et al:Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698-705, 1996
  pubmed

• 40) Boissier S, Magnetto S, Frappart L, et al:Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890-3894, 1997
  pubmed

• 41) Magnetto S, Boissier S, Delmas PD, et al:Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int Cancer 83:263-269, 1999
  pubmed

• 42) Boissier S, Ferreras M, Peyruchaud O, et al:Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949-2954, 2000
  pubmed

• 43) Virtanen SS, V n nen HK, H rk nen PL, et al:Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62:2708-2714, 2002

• 44) Teronen O, Heikkil P, Konttinen YT, et al:MMP inhibition and down-regulation by bisphosphonates. Ann N Y Acad Sci 878:453-465, 1999

• 45) Stearns ME:Alendronate blocks TGF-1 stimulated collagen l degradation by human prostate PC3-ML cells. Clin Exp Metastasis 16:332-339, 1998

• 46) Stearns ME, Wang M:Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3ML cells in SCID mice. Clin Exp Metastasis 16:693-702, 1998

• 47) Kunzmann V, Bauer E, Wilhelm M:Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340:737-738, 1999
  pubmed

• 48) Das H, Wang L, Kamath A, et al:Vgamma2Vdelta2 Tcell receptor-mediated recognition of amino-bisphosphonates. Blood 98:1616-1618, 2001

• 49) Kato Y, Tanaka Y, Miyagawa F, et al:Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol 167:5092-5098, 2001
  pubmed

• 50) Wilhelm M, Kunzmann V, Eckstein S, et al:Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102:200-206, 2003
  pubmed

• 51) Dieli F, Gebbia N, Poccia F, et al:Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 15:102:2310-2311, 2003

• 52) Hilner BE, Ingle JN, Chelbowski RT, et al:American Society of Clinical Oncology:American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003

• 53) Berenson JR, Hillner BE, Kyle RA, et al:American Society of Clinical Oncology Bisphosphonates Expert Panel:American Society of Clinical Oncology clinical practice guidelines:the role of bisphosphonates in multiple myeloma. Clin Oncol 20:3719-3736, 2002

• 54) Saad F, Gleason DM, Murray R, et al:Zoledronic Acid Prostate Cancer Study Group. A randomized, placebocontrolled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002

• 55) Rosen LS, Gordon D, Tchekmedyian S, et al:Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase III, double-blind, randomized trial the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003

• 56) Lipton A, Zheng M, Seaman J:Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98:962-969, 2003
  pubmed

P.43 掲載の参考文献

• 1) Fields HL, Heinricher MM, Mason P:Neurotransmitters in nociceptive modulatory circuits. Annu Rev Nuerosci 14:219-245, 1991
  pubmed

• 2) Miki K, Zhou QQ, Guo W, et al:Changes in gene expression and neuronal phenotype in brain stem pain modulatory circuitry after inflammation. Journal of Neurophysiology 87:750-60, 2002
  pubmed

• 3) Imbe H, Iwata K, Zhou QQ, et al:Orofacial deep and cutaneous tissue Inflammation and trigeminal neuronal activation. Cells Tissue Organs 169:238-247, 2001
  pubmed

• 4) Imanaka T, Shichikawa K, Inoue K, et al:Increase in age at onset of rheumatoid arthritis in Japan over 30 year period. Ann Rheum Dis 56:313-316, 1997
  pubmed

• 5) Lee D, Weinblatt M:Rheumatoid arthritis. Lancet 358:903-911, 2001
  pubmed

• 6) Kidd BL, Urban LA:Mechanism of inflammatory pain. Br J Anaesth 87:1-9, 2001
  pubmed

• 7) Schaible HG, Grubb BD:Afferent and spinal mechanism of joint pain. PAIN 55:5-54, 1993
  pubmed

• 8) Jolliffe VA, Anand P, Kidd BL:Assesment of cutaneous sensory and autonomic axon reflexes in rheumatoid arthritis. Ann Rheum Dis 54:251-255, 1995

• 9) Opree A, Kress M:Involvement of the pro-inflammatory cytokines tumor necrosis factor-α, IL-1βand IL-6 but not IL-8 in the development of heat Hyperalgesia:effect on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 20:6289-6293, 2000

• 10) Wendler J, Hummel T, Reissinger M, et al:Patients with rheumatoid arthritis adapt differently to repetitive painful stimuli compared to healty controls. J Clin Neurosci 8:272-277, 2001

• 11) Morris VH, Cruwys S, Kidd B:Characterisation of capsaicin-induced mechanical Hyperalgesia as a maker for altered nociceptive processing in patients with rheumatoid arthritis. Pain 71:179-186, 1997

• 12) Ash G, Dickens C, Creed F, et al:The effect of dothiepin on subjects with rheumatoid arthritis and depression. Rheumatology 38:959-967, 1999
  pubmed

• 13) Russell IJ, Orr MD, Littman B, et al:Elevated cerebrospinal fluid levels of substance P in patients with the FM. Arthritis Rheum 37:1593-1561, 1994

• 14) Russell IJ, et al. Cerebrospainal fluid biogenic amine metabolites in FM. Arthritis Rheum 35. 550-556, 1992

• 15) Russel IJ, Michalek JE, Vipraio GA, et al:Platelet 3H-Imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. The Journal of Rheumatology 19:104-109, 1992

• 16) Nishioka M:Clinical effect of novel compound to Fibromyalgia-Neurotropin. International symposium of Fibromyalgia, Tokyo, 2004

• 17) Bennett RM:Emerging concepts in the neurobiology of chronic pain:evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 74:385-398, 1999
  pubmed

• 18) 福岡哲男:痛みの基礎知識 (痛覚伝達の調整機能). 痛みの診療 (柴田政彦, 吉矢生人, 具下節編), pp22-24, 東京, 克誠堂出版, 2000

• 19) 三木健司, 柴出政彦:痛みの基礎知識 (Pathological painのメカニズム). 痛みの診療 (柴田政彦, 吉矢生人, 真下節編), pp25-33, 東京, 克誠堂出版, 2000

P.49 掲載の参考文献

• 1) Parrot JM:Sur les malformations achondroplasiques et le dieu Ptah. Bull Soc Antropol 1:298, 1878

• 2) 平成13年度骨系統疾患全国登録一覧. 日本整形外科学会骨系統疾患委員会編, 2001

• 3) Rousseau F, Bonaventure J, Legeai-Mallet L, et al:Amutations in the gene encoding fibroblast growth factor receptor 3 in achondroplasia. Nature 371:252-254, 1994

• 4) Shiang R, Thompson LM, Zhu YZ, et al:Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78:335-342, 1994
  pubmed

• 5) Matsui Y, Yasui N, Kimura, et al:Genotype phenotype correlation in achondroplasia and hypochondroplasia. J Bone Joint Surg Br 80:1052-1056, 1998
  pubmed

• 6) Colvin JS, Bohne BA, Harding GW, et al:Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12:390-397, 1996
  pubmed

• 7) Deng C, Wynshaw-Boris A, Zhou F, et al:Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911-921, 1996
  pubmed

• 8) 立花克彦, 諏訪成三., 西山宗六ら:全国調査に基づいた軟骨無形成症患児の身長の検討. 小児科診療60:1363-1369, 1997

• 9) 大西五三男:軟骨無形成症の長期フォローアップ. 小児内科31:1209-1212, 1999

• 10) Shouhat M, Tick D, Barakat S, et al:Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. J Clin Endocrinol Metab 81:4033-4037, 1996

• 11) 安井夏生:Achondroplasia症に対する両下肢延長術. 手術43:1589-1597, 1989

• 12) Uematsu S, Wang H, Kopits SE, et al:Total craniospinal decompression in achondroplastic stenosis. Neurosurgery 35:250-257, 1994
  pubmed

• 13) 熊谷康佑, 高橋忍, 勝浦章知ら:軟骨無形成症に伴う広範脊柱管狭窄症に対する頸髄除圧術の1例. 臨床整形外科38:1545-1550, 2003

P.59 掲載の参考文献

• 1) 佐藤巌, 大河内敏行, 大和田哲雄ら:外側型腰椎椎間板ヘルニアの病態と手術成績. 日本脊椎外科学会雑誌 9:379, 1998
  Medical*Online

• 2) 成尾政圀, 小柳英一, 浦門操ら:外側型腰椎椎間板ヘルニアの臨床症状. 脊椎脊髄7:585-590, 1994

• 3) Macnab I:Negative disc exploration. J. Bone Joint Surg 53A:891-903, 1971

• 4) 久野木順一:外側型腰椎椎間板ヘルニアのMRIによる評価と精度. 脊椎脊髄7:573-578, 1994

• 5) 佐藤巌, 大河内敏行, 大和田哲雄ら:腰椎椎間板ヘルニアにおけるL5神経根障害. 脊柱管内ヘルニアと外側型ヘルニアの臨床症状の比較. 日整会誌73:S128, 1999

• 6) 久野木順一:外側型腰椎椎間板ヘルニアに対するMRIの有用性と問題. 脊椎脊髄10:205-212, 1997

• 7) 大和田哲雄, 大河内敏行, 山本利美雄:腰椎椎間板ヘルニアに対する PLIF. 整形外科New Mook 2:212-222, 1997

P.67 掲載の参考文献

• 1) Nachemson A:The lumbar spine:an orthopedic challenge. Spine 1:59-71, 1976

• 2) Deyo RA, Phillips WR:Low back pain:aprimary care challenge. Spine 21:2826-2832, 1996

• 3) Staal JB, Hlobil H, van Tulder MW, et al:Return-to-work interventions for low back pain:a descriptive review of contents and concepts of working mechanisms. Sports Medicine 32:251-267, 2002
  pubmed

• 4) 菊地臣一:腰痛概念の革命-生物学的アプローチから心理・社会的アプローチへの転換. 心身医学42:105-110, 2002

• 5) Coste J, Delecoenillerie G, Cohende Lara A, et al:Clinical course and prognostic factors in acute low back pain:an inception cohort study in primary care practice. BMJ 308:577-580, 1994

• 6) Hazard RG, Haugh LD, Reid S, et al:Early prediction of chronic disability after occupatinal low back injury. Spine 21:945-951, 1996

• 7) Lindstrom I, 0hlund C, Eek C, et al:Mobility strength and fitness after a graded activity program for patients with subacute low back pain:arandomized prospective clinical study with behavioral therapy approach. Spine 17:641-652, 1992

• 8) Elnaggar IM, Nordin M, Sheikhzadeh A, et al:Effect of spinal flexion and extension exercise on low back pain and spinal mobility in chronic mechanical low back pain patients. Spine 16:967-972, 1991
  pubmed

• 9) Turner JA, Clancy S, Mc Quade KJ, et al:Effectiveness of behavioral therapy for chronic low back pain:a component analysis. J Consult Clin Psychol 58:573-579, 1990
  pubmed

• 10) Frost H, Klaber Moffet JA, Moser JS, et al:Randomized controlled trial for evaluation of fitness programme for patients with chronic low back pain. BMJ 310:151-154, 1995

• 11) Werneke MW, Harris DE, Lichter RL:Clinical effectiveness of behavioral signs for screening chronic low back pain patients in a work-oriented physical rehabilitation program. Spine 18:2412-2418, 1993

• 12) Pransky G, Benjamin K, Hill-Fotouhi C:Work-related outcomes in occupatinal low back pain:a multidimensional analysis. Spine 27:864-870, 2002

• 13) Lehmann TR, Spratt KF, Lehmann KK:predicting long term disability in low back injured workers presenting to spine consultant. Spine 18:1103-1112, 1993
  pubmed

• 14) Kaplansky BD, Wei FY, Reecer MV:Prevention strategies for occupational low back pain. Occupational Medicine 13:33-45, 1998

• 15) Skouen JS, Grasdal AL, Haldorsen EMH, et al:Relative costeffectiveness of extensive and light multidisciplinary treatment programs versus treatment as usual for patients with chronic low back pain on long-term sick leave. Spine 27:901-910, 2002
  pubmed

• 16) 北原雅樹:慢性疼痛の集学的治療 (理論的基礎と日本での展開). ペインクリニック24:1371-1378, 2003.

• 17) 菊地臣一:腰痛. 医学書院, 2003

• 18) 有田親史:高齢者の姿勢と痛み. リウマチ病セミナーXII(七川歡次監修), pp117-128, 大阪, 永井書店, 2001

• 19) 真下 節:慢性疼痛とは. 臨床神経科学20:1098-1099, 2002

• 20) 中井吉英, 町田英世, 阿部哲也:心と痛み. 整形外科51:893-896, 2000

• 21) 熊澤孝明:急性痛と慢性痛のメカニズム. 現代医療34:5-11, 2002

• 22) 佐藤英俊, 十時忠秀:メイヨークリニックをモデルにした慢性疼痛に対する集学的治療の実践と課題. ペインクリニック24:1344-1351, 2003

• 23) 豊川秀樹, 塩谷正弘,:NTT東日本関東病院での実践と課題. ペインクリニック24:1365-1370, 2003

• 24) Langley GB, Sheppeard H:The visual analogue scale:1st use in pain measurement. Rheumatol Int 5:145-148, 1985

• 25) Melzack R:The Mc Gill pain questionnaire:major properties and scoring merthods. Pain 1:277-299, 1975

• 26) 佐藤英俊, 十時忠秀:痛みの評価法. 日本医師会雑誌119:S34-S37, 1998

• 27) 福原俊一 :Mos short form 36 items health survey新しい健康アウトカム指標. 厚生の指標46:40-45, 1999

• 28) Roland M, Morris R:A study of the natural history of back pain:part 1:development of a reliable and sensitive measure of disability in low-back pain. Spine 8:141-144, 1983

• 29) Roland M, Fairbank J:The Roland-Morris disability questionnaire and the Oswestry disability questionnaire. Spine 25:3115-3124, 2000
  pubmed

• 30) Love AW, Peck DL:The MMPI and psychological factors in chronic low back pain:a review. Pain 28:1-12, 1987

• 31) Snook SH, Webster BS, Mc Gorry RW, et al:The reduction of chronic nonspecific low back pain through the control of early morning lumbar flexion:a randomized controlled trial. Spine 23:2601-2607, 1998
  pubmed

• 32) Mayer T, Gatchel R, Kishino N, et al:Objective assesment of spine function following industrial injury:a prospective study with comparison group and one-year follow-up. Spine 10:482-493, 1985

• 33) Hazard RG, Fenwick JW, Kalisch SM, et al:Functional restoration with behavioural support:a one year prospective study of patients with chronic low back pain. Spine 14:157-161, 1989
  pubmed

• 34) Burke SA, Harms-Constas CK, Aden PS:Return to work/work retention outcomes of a functional restoration program:a multi-center prospective study with a comparison group. Spine 19:1880-1886, 1994

• 35) Mitchell RI, Carmen GM:The functional restoration approach to the treatment of chronic pain in patients with soft tissue and back injuries. Spine 19:633-642, 1994

• 36) Linton S, Bradley L, Jensen I, et al:The secondary prevention of low back pain:a controlled study with follow up. Pain 36:197-207, 1989
  pubmed

• 37) Oland G, Tveiten G:Atrial of modern rehabilitation for chronic low back pain and disability. Spine 16:457-459, 1991

• 38) Bendix AF, Bendix T, Labriola M, et al:Functional restoration for chronic low back pain:two-year follow-up of two randomized clinical trials. Spine 23:717-725, 1998
  pubmed

• 39) 村上孝徳, 山下敏彦, 横串算敏ら:慢性腰痛症に対する集学的治療の試み. 日本脊椎脊髄病学会雑誌14:232, 2003

• 40) 2002-2003クリニカル・エビデンス日本語版. 日経BP社, 2002

• 41) 栗原 章:職業性腰痛の現状と展望. 日本腰痛会誌8:10-15, 2002

• 42) Hadler N:Workers with disabling back pain. New England Journal of Medicine 337:341-343, 1997
  pubmed

• 43) 劉 宝龍:職業性腰痛に対する予防対策の評価. 岡山医学会雑誌109:165-172, 1997

• 44) The Back Letter 18:3-5, 2003
  pubmed

• 45) 平成15年グラフでみる世帯の状況-国民生活基礎調査 (平成13年) の結果から. 厚生統計協会. 2003

P.85 掲載の参考文献

• 1) 西林保朗:高齢者後轡の病態. リウマチ病セミナーV (七川歓次監修), pp121-132, 大阪, 永井書店, 1994

• 2) Hilliquin P, Menkes CJ, Laussadi S, et al:Camptocormia in the elderly. A new entity by paravertebral muscle involvement? Rev Rheum Mal Osteoartic 59:169-175, 1992 [Article in French]

• 3) Poullin P, Daumen-Legre V, Serratrice G:Camptocormia in the elderly patient:myopathy or muscular dystonia? Rev Rheum Ed Fr 60:159-161, 1993 [Article in French]
  pubmed

• 4) Laroche M, Delisle MB:Primary camptocormia in a paravertebral myopathy. Rev Rheum Ed Fr 61:481-484, 1994 [Article in French]

• 5) 有田親史:高齢者の姿勢と痛み. リウマチ病セミナーXII (七川歓次監修), pp117-128, 大阪, 永井書店, 2001

• 6) 竹光義治, 加茂祐樹, 熱田裕次, ほか:高齢者の各種脊柱後彎と腰痛. 整・災外36:901-907, 1993

• 7) 大川 淳, 請川 洋, 宮沢あかね, ほか:高齢者の腰曲がり歩行と腰椎アライメント. 臨整外28:887-893, 1993.

• 8) Renier JC:Reducible kyphosis, camptocormia, proclinorachis. Rev Rheum Ed Fr 60:943, 1993 [Article in French]

• 9) Feriha O, Aytul M, Hasan M:A case of camptocormia (bent spine) secondary to early motor neuron disease. Behabv Neurol 15:51-54, 2004

• 10) Djaldetti R, Mosberg-Galili R, Sroka H, et al:Camptocormia (bent spine) inpatients with Parkinson's disease-characterization and possible pathogenesis of an unusual phenomenon. Mov Disord 14:443-447, 1999

• 11) Oerlemans WG, de Visser M:Dropped head syndrome and bent spine syndrome:two separate clinical entities or different manifestations of axial myopathy? J Neurol Neurosurg Psychiatry 65:258-259, 1998
  pubmed

• 12) Serratrice G, Pouget J, Pellissier JF:Bent spine syndrome. J Neurol Neurosurg Psychiatry 60:51-54, 1998

• 13) Macleod AD:Head drop and camptocormia. J Neurol Neurosurg Psychiatry 74:692, 2003
  pubmed

• 14) Umapathi T, Chaudhry V, Cornblath D, et at:Head drop and camptocormia. J Neurol Neurosurg Psychiatry 73:1-7, 2002
  pubmed

• 15) Tsikoudas A, England RJ, Fenwick JD, et al:Inflammatory myositis:a rare differential diagnosis of a neck lump. ORL J Otorhinolaryngol Relat Spec 63:325-327, 2001
  pubmed

• 16) Horiuchi M, Uehara K, Komo T, et al:A case of elderly onset Parkinson's disease complicated by dropped head syndrome. Nippon Ronen Igakkai Zasshi 38:693-695, 2001 [Article in Japanese]
  pubmed

• 17) Biran I, Cohen O, Diment J, et al:Focal, steroid responsive myositis causing dropped head syndrome. Muscle Nerve 22:769-771, 1999
  pubmed

• 18) Jaster JH, Bertorini TE, Swims MP, et al:Cervical kyphosis after resolution of myopathic head drop. A case report. Spine 21:2023-2025, 1996

• 19) Delcey V, hachulla E, Michon-Pasturel U, et al:Camptocormia:a sign of axial myopoathy. Report of 7 cases. Rev Med Interne 23:144-154, 2002 [Article in French]
  pubmed

• 20) Delisle MB, Laroche M, Dupont H, et al:Morphological analysis of paraspinal muscles:comparison of progressive lumbar kyphosis (camptocormia) and narrowing of lumbar canal disc protrusion. Neuromuscul Disord 3:579-582, 1993

• 21) Karbowski K:The old and the new camptocormia. Spine 15:1494-1498, 1999

• 22) Legaye J, Dimboiu D:Camptocormia or reducible lumbar kyphosis in elderly subjects. Apropos of 2 cases of lipoid degeneration of the paravertebral muscles. Acta Orthop Belg 61:278-281, 1995 [Article in French]
  pubmed

• 23) Rajmohan V, Thomas B, Sreekumar K:Case study:camptocormia, a rare conversion disorder. J Am Acad Child Adlesc Psychiatry 43:1168-1170, 2004
  pubmed

• 24) Lin JJ:Camptocormia in Parkinson's disease. Acta Neurol Taiwan 13:4647, 2004

• 25) Holler I, Dirmberger G, Pirker W, et al:Camptocormia in idiopathic Parkinson's disease:[(123)I] beta-CIT SPECT and clinical characteristics. Eur Neurol 50:118-120, 2003

• 26) Van Gerpen JA:Camptocormia secondary to early amyotrophic lateral sclerosis. Mov Disord 16:358-360, 2001
  pubmed

• 27) Nieves AV, Miyasaki JM, Lang AE:Acute onset dystonic campocormia caused by lenticular lesions. Mov Disord 16:177-180, 2001
  pubmed

• 28) Wuderlich S, Csoti I, Reiners K, et al:Camptocormia in Parkinson's disease mimicked by focal myositis of the paraspinal muscles. Mov Disord 17:598-600, 2002

• 29) Hachulla E:Dermatomyositis and polymyositis:clinical aspects and treatment. Ann Med Int 152:455-464, 2001 [Article in French]

• 30) Schabitz WR, Glatz K, Schuhan C, et al:Severe forward flexion of the trunk in Parkinson's disease:focalmyopathy of the paraspinal muscles mimicking camptocormia. Mov Disord 18:408-414, 2003
  pubmed

• 31) Mahjneh I, Marconi G, Paetau A, et al:Axial myopathyan unrecognized entity. J Neurol 249:730-734, 2002

• 32) Inzerberg R, Hattori N, Nisipeanu P, et al:Camptocormia, axial dystonia, and parkinsonism:phenotypic heterogeneity of a parkin mutation. Neurology 22:1393-1394, 2003

• 33) Slawek J, Derejko M, Lass P:Camptocormia as a form of dystonia in Parkinson's disease. Eur J Neurol 10:107-108, 2003
  pubmed

• 34) Reichel G, Kirchhofer U, Stenner A:Camptocormia-segmental dystonia. Proposal of a new definition for an old disease. Nervenarzt 72:281-285, 2001
  pubmed

• 35) 岡本幸市:パーキンソン症候群を起こす疾患にはどのようなものがあるか?パーキンソン病Q&A (平井俊策編), pp26-27, 大阪, 医療ジャーナル社, 2001

• 36) Abdulhadi HM, Kerrigan DC:Camptocormia:abiomechanical analysis. A case report. Am J Phys Med Rehabil 75:310-313, 1996

• 37) Schranz C, Meinck HM:Primary neurogenic and myogenic disorders of posture. Orthopade 33:580-590, 2004 [Article in German]

• 38) 西田康太郎:脊椎疾患に対する遺伝子治療の試み. リウマチ病セミナーXIV, (七川歓次監修), pp179-183, 大阪, 永井書店, 2003

• 39) 小谷義久, 鐙 邦芳, 三浪明男:人工椎間板. 現代医療34:631-633, 2002

• 40) 武政龍一:骨粗鬆症脊椎における骨内注人療法. リウマチ病セミナーXII (七川歓次監修), pp253-264, 大阪, 永井書店, 2001

P.92 掲載の参考文献

• 1) Yoshino S, S Uchida:Sexual problems of women with rheumatoid arthritis. Arch Phys Med Rehabil 62:122-123, 1981

• 2) Kraaimaat FW, et al:Intrusiveness of rheumatoid arthritis on sexuality in male and female patients living with a spouse. Arthritis Care Res 9:120-125, 1996
  pubmed

• 3) Herstein ARH Hill, K Walters:Adult sexuality and juvenile rheumatoid arthritis. J Rheumatol 4:35-39. 1977

燐・カルシウム代謝

P.99 掲載の参考文献

• 1) Begerow B, Pfeifer M, Pospeschill M, et al:Time since vertebral fracture:an important variable concerning quality of life in patients with postmenopausal osteoporosis. Osteoporos Int 10:2633, 1999

• 2) 福原俊一ら編:SF36日本語版マニュアルVersion1, 2, パブリックヘルスリサーチセンター, 2001

• 3) 福原俊一:臨床のためのQOL評価ハンドブック (池上直己, 福原俊一, 下妻晃二郎, 池出俊也編), pp2-7, 東京, 医学書院, 2001

• 4) Lips P et al:Quality of life as outcome in the treatment of osteoporosis:The development of a questionnaire for quality of life by European foundation for osteoporosis. Osteoporosis Int 7:36-38, 1997
  pubmed

• 5) Martin AR, Sornay-Rendu E, Chandler JM, et al:The impact of osteoporosis on quality-of-life:the OFELY cohort. Bone Jul 31:32-36, 2002
  pubmed

• 6) Nevitt MC, Thompson DE, Black DM, et al:Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 160:77-85, 2000

• 7) Silverman SL:The osteoporosis assessment questionnaire (OPAC):a reliable and valid self assessment measure of quality of life in osteoporosis. J Miner Res 8:s343, 1993

• 8) Silverman SL, Minshall ME, shen W, et al:The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis:Results from the multiple outcomes of raloxifene evaluation study. Arthritis Rheumatism 44:2611-2619, 2001
  pubmed

• 9) 高橋栄明, 日本骨代謝学会骨粗鬆症患者QOL評価検討委員会:日本骨代謝学会骨粗鬆症患者QOL評価質問 表1999年版, 日骨代謝誌17:65-84, 1999

• 10) 高橋栄明, 日本骨代謝学会骨粗鬆症患者QOL評価検討委員会:日本骨代謝学会骨粗鬆症患者QOL評価質問 表1999年版の試用と2000年版の作成, 日骨代謝誌18:83-101, 2001

• 11) 高橋栄明:骨粗鬆症患者に対するQOL評価;各種評価尺度の比較. 骨粗鬆症治療2:129-134, 2003

• 12) 田中清:genericなQOLの指標SF36を用いたエルカトニンの薬効判定の試み. Osteoporosis Jpn 8:675-679, 2000

• 13) 田中清, 楊 鴻生, 釜江清夫ら:骨粗鬆症患者におけるQOL評価;SF36, EQ5D, JOQOLの比較検討およびQOL低下要因の検討. Osteoporosis Jpn 10:184, 2002

• 14) 楊 鴻生:QOLと治療指針. 骨粗鬆症治療1:39-43, 2002

• 15) 楊 鴻生:日本人骨粗鬆症患者のQOLに関する研究, 長寿科学国際共同研究事業, 分担研究報告書, 平成14年度総括

• 16) 楊 鴻生, 田中 清, 釜江清夫ら:QOL評価法を用いたエルカトニン治療効果判定の試み. Osteoporosis Jpn 10:184, 2002

検査法

P.107 掲載の参考文献

• 1) 池田修一:アミロイドーシスの診断基準・病型分類・重症度. 内科85:1498-1504, 2000

• 2) 志水止敏:アミロイドーシスと骨関節変化. リウマチ病セミナーVIIl (七川歡次監修), pp26-31, 大阪,永井書店, 1996

• 3) 圓尾宗司:透析に関連して出現するリウマチ症状. リウマチ病セミナーXI (七川歡次監修), pp66-75, 大阪, 永井書店, 2000

• 4) 中井秀紀:二次性アミロイドーシスの早期発見と治療 (七川歡次監修), pp168-173, 大阪, 永井書店, 2003

• 5) Ikeda S, Nakazato M, Ando Y, et al:Familial transthyretin-type amyloid polyneuropathy in Japan. Neurology 58:1001-1007, 2002
  pubmed

• 6) Kyle RA, Gertz MA, Linke RP:Amyloid localized to tenosynovium at carpal tulmel release. Immunohistochemical identification of amyloid type. Am J Clin Pathol 97:250-253, 1992
  pubmed

• 7) Kyle RA, Gertz MA:Primary systemic amyloidosis:clinical and laboratory features in 474 cases. Semin Helnatol 32:45-59, 1995
  pubmed

• 8) Sigueira-Filho AG, Cunha CLP, Tajik AJ, et al:M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 63:188-196, 1981

• 9) Hawkins PN, Lavender JP, Pepys MB:Evaluation of systemic amyloidosis by scintigraphy with 123 I-labelled serum amyloid P component. N Engl J Med 323:508-513, 1990
  pubmed

• 10) Wizenberg TA, Muz J, Sohn YH, et al:Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J 103:468-473, 1982
  pubmed

• 11) Hongo M, Hirayama J, Fujii T, et al:Early identification of amyloid heart disease by technetium-99m-pyrophosphate scintigraphy:a study with familial amyloid polyneuropathy. Am Heart J 113 654-662, 1987
  pubmed

• 12) Misu K, Hattori N, Nagamatsu M, et al:Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features, Brain 122:1951-1962, 1999
  pubmed

• 13) Takei Y, Ikeda S, Hashikura Y, et al:Partial-liver transplantation to treat familial amyloid polyneuropathy:follow-up of 11 patients. Ann Intern Med 131:592-595, 1999
  pubmed

• 14) Takei Y, Hattori T, Gono T, et al:Senile systemic amyloidosis presenting as bilateral carpal tunnel syndrome. Amyloid. J Protein Folding Disord 9:252-255, 2002

• 15) Westermark P, Bergstrom J, Solomon A, et al:Transthyretin-derived senile systelnic amyloidosis:clinicopathologic and structural considerations. Amyloid:J Protein Folding Disord 10 Suppl 1:48-54, 2003

• 16) Gono T, Matsuda M, Dohi N, et al:Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med 42:72-77, 2003
  pubmed

• 17) Ikeda S, Takei Y, Hashikura Y:Liver transplantation as treatment for neurological disorders. Expert Rev Neurotherapeutics 3:547-555, 2003

P.117 掲載の参考文献

• 1) Mccarty DJ:Synovial Fluid. Arthritis and Nlied Conditions (In Koopman WJ editor), pp83-104, Philadelphia, Lippincott Williams & Wilkins, 2001

• 2) Yuan GH, Masuko-Hongo K, Kato T, et al:Immunologic Intervention in the pathogenesis of osteoarthritis. Arthritis Rheum 48:602-611, 2003
  pubmed

• 3) Freemont AJ, Denton J:Synovial fluid analysis. Rheumatology (In Hochberg MC, Silman AJ, Smolen JS, et al. editors), pp227-232, New York, Mosby, 2003

• 4) Aigner T, Kim A:Apoptosis and cellular vitality. Arthritis Rheum 46:1986-1996, 2002

• 5) Henrotin YE, Bruckner P, Pujol J-PL:The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthr Cartilage 11:747-755, 2003

• 6) Pelletier JP, Pelletier JM, Abramson SB:Osteoarthritis, an inflamatory disease. Arthritis Rheum 44:1237-1247, 2001

• 7) Karan A, Karan MA, Vural P, et al:Synovial fluid nitric oxide levels in patients with knee osteoarthritis. Clin Rheumatol 22:397-399, 2003
  pubmed

• 8) Jang D, Murrell GA:Nitric oxide in arthritis, Free Radic Biol Med 24:1511-1519, 1998
  pubmed

• 9) Poole AR:What type of cartilage repair are we attempting to attain? JBJS 85-A:40-44, 2003

• 10) Black RA, Rauch CT, Kolosky CJ, et al:Ametalloproteinase disintegrin that relaeases tumor-necrosis factor-alfa from cells. Nature 385:729-733, 1997

• 11) Abbaszade I, Lie RQ, Yang F, et al:Cloning and characterization of ADAMTS11, an aggrecanase from ADAMTS family. J Biol Chem 274:23443-23450, 1999

• 12) Tortorella MD, Paratta M, Liu RQ, et al:Sites of aggrecan cleavage by recombinant human aggrecanse-1 (ADAMTS-4). JBiol Chem 275:18566-18573, 2000

• 13) Tortorella MD, Malfait AM, Deccico C, et al:The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthr Cartilage 9:539-552, 2001

• 14) Peter G, Magna MHA, Reeves LM, et al:Cloning, Expression, and Type II Collagenolytic activity of Matrix Metalloproteinase-13 from human osteoarthritic Cartilage. J Clin Invest 97:761-768, 1996

• 15) Stoop R, Buma P, van der Kraan PM, et al:Type II collagen degradation in articular cartilage fibrillation after anterior cruciate ligament transectio in rats. Osteoarthr Cartilage 9:308-315, 2001

• 16) Pratta MA, Yao W, Decicco C, et al:Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem 278:45539-45545, 2003
  pubmed

• 17) Ishiguro N, Ito T, Ito D, et al:Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover:Analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheum 42:129-136, 1999

• 18) Myers SL:Synovial fluid markers in osteoarthritis. Rheum Dis Clin North Am 25:433-449, 1999
  pubmed

• 19) Hollander AP, Heathfield TF, Webber C, et al:Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 93:1722-1732, 1994
  pubmed

• 20) Christgau S, Garnero P, Fledelius C, et al:Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29:209-215, 2001
  pubmed

• 21) Garnero P, Ayral X, Rousseau JC, et al:Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46:2613-2624, 2002
  pubmed

• 22) Poole AR:Can serum biomarker assays measure the progression of cartilage degeneration in osteoarthritis? Arthritis Rheum 46:2549-2552, 2002
  pubmed

生物学的反応

P.127 掲載の参考文献

• 1) Cutolo M, Seriolo B, Craviotto C, et al:Circadian rhythms in RA. Ann Rheum Dis 62:593-596, 2003
  pubmed

• 2) White WB, LaRocca GM:Chronopharmacology of cardiovascular therapy. Blood Press Monit 7:199-207, 2002Review
  pubmed

• 3) Lavery DJ, Schibler U:Circadian transcription of the cholesterol 7 alpha hydroxylase gene may involve the liver-enriched bZIP protein DBP. Genes Dev 7:1871-1884, 1993
  pubmed

• 4) Hara R, Wan K, Wakamatsu H, et al:Restricted feeding entrains liver clock without participation of the suprachiasmatic nucleus. Genes Cells 6:269-278, 2001
  pubmed

• 5) Reppert SM, Weaver DR:Coordination of circadian timing in mammals. Nature 418:935-941, 2002 Review
  pubmed

• 6) Hannibal J:Neurotransmitters of the retino-hypothalamic tract. Cell Tissue Res 309:73-88, 2002 Review
  pubmed

• 7) Yokota S, Yamamoto M, Moriya T, et al:Involvement of calcium-calmodulin protein kinase but not mitogen-activated protein kinase in light-induced phase delays and Per gene expression in the suprachiasmatic nucleus of the hamster. J Neurochem 77:618-627, 2001

• 8) Minami Y, Furuno K, Akiyama M, et al:Pituitary adenylate cyclase-activating polypeptide produces a phase shift associated with induction of mPer expression in the mouse suprachiasmatic nucleus. Neuroscience 113:37-45, 2002
  pubmed

• 9) Kannaway DJ:Resetting the suprachiasmatic nucleus clock. Front Biosci 9:56-62, 2004

• 10) Horikawa K, Yokota S, Fuji K, et al:Nonphotic entrainment by 5-HTIA/7 receptor agonists accompanied by reduced Per1 and Per2 mRNA levels in the suprachiasmatic nuclei. J Neurosci 20:5867-5873, 2000

• 11) Hogenesch JB, Panda S, Kay S, et al:Circadian transcriptional output in the SCN and liver of the mouse. Novartis Found Symp 253:171-180, 2003Review
  pubmed

• 12) Terazono H, Mutoh T, Yamaguchi S, et al:Adrenergic regulation of clock gene expression in mouse liver. Proc Natl Acad Sci USA 100:6795-6800, 2003
  pubmed

• 13) Mistlberger RE:Circadian food-anticipatory activity:formal models and physiological mechanisms. Neurosci Biobehav Rev 18:171-195, 1994Review
  pubmed

• 14) Nikaido T, Moriya T, Takabayashi R, et al:Sensitization of methamphetamine-induced disorganization of daily locomotor activity rhythm in male rats. Brain Res 845:112-116, 1999
  pubmed

• 15) Wakamatsu H, Yoshinobu Y, Aida R, et al:Restricted-feeding-induced anticipatory activity rhythm is associated with a phase-shift of the expression of mPer1 and mPer2 mRNA in the cerebral cortex and hippocampus but not in the suprachiasmatic nucleus of mice. Eur J Neurosci 13:1190-1196, 2001

• 16) Rutter J, Reick M, McKnight SL:Metabolism and the control of circadian rhythms. Annu Rev Biochem 71:307-331, 2002Review
  pubmed

• 17) Duncan WC Jr, Johnson KA, Wehr TA:Decreased sensitivity to light of the photic entrainment pathway during chronic clorgyline and lithium treatments. J Biol Rhythms 13:330-346, 1998
  pubmed

• 18) Duncan WC Jr, Johnson KA, Wehr TA:5-HT agonist-induced phase-advances of the circadian pacemaker are diminished by chronic antidepressant drug treatment. Brain Res 815:126-130, 1999
  pubmed

• 19) Wagner S, Castel M, Gainer H, et al:GABA in the mammalian suprachiasmatic nucleus and its role in diurnal rhythmicity. Nature 387:598-603, 1997
  pubmed

• 20) Liu C, Reppert SM:GABA synchronizes clock cells within the suprachiasmatic circadian clock. Neuron 25:123-128, 2000
  pubmed

• 21) Yokota SI, Horikawa K, Akiyama M, et al:Inhibitory action of brotizolam on circadian and light-induced per1 and per2 expression in the hamster suprachiasmatic nucleus. Br J Pharmacol 131:1739-1747, 2000
  pubmed

• 22) Cutolo M, Seriolo B, Craviotto C, et al:Circadian rhythms in RA. Ann Rheum Dis 62:593-596, 2003
  pubmed

P.138 掲載の参考文献

• 1) 松野博明:Anti Citrulline-containing peptide antibody. リウマチ病セミナー XIV (七川歓次監修), pp96-101, 大阪, 永井書店, 2003

• 2) Reveille JD, Solomon DH, The American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidlines:Evidence-based guidelines for the use of immunologic tests:anticentromere, Scl-70 and nuclear antibodies, Arthritis Rheum (Arthritis Care Res) 49:399-412, 2003

• 3) Palosuo T, Tilvis R, Strandberg T, et al:Filaggrin related antibodies among the aged. Ann Rheum Dis 62:261-263, 2003
  pubmed

• 4) Lee DM, Schur PH:Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870-874, 2003
  pubmed

• 5) Zeng X, Ai M, Tian X, et al:Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 30:1451-1455, 2003
  pubmed

• 6) Meyer O, Labarre C, Dougados M, et al:Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120-126, 2003
  pubmed

• 7) Vencovsky J, Machacek S, Sedova L, et al:Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427-430, 2003
  pubmed

• 8) Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, et al:The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 30:1691-1695, 2003
  pubmed

• 9) van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al:Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 50:709-715, 2004
  pubmed

• 10) Vittecoq O, Incaurgarat B, Jouen-Beades F, et al:Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 135:173-180, 2004

• 11) Aho K, Palosuo T, Lukka M, et al:Antifilaggrin antibodies in recent-onset arthritis. Scand J Rheumatol 28:113-116, 1999
  pubmed

• 12) Yamasaki Y, Akaogi J, Narain S, et al:Reactivity of antibodies to cyclic citrullinated peptide (CCP) and unmodified peptide in systemic rheumatic diseases, Arthritis Rheum 50 (Suppl 9):S523, 2004

• 13) Baeten D, Peene I, Union A, et al:Specific presence of intracellular citrullinated proteins inrheumatoid arthritis synovium. Arthritis Rheum 44:2255-2262, 2001

• 14) Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al:The Major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha-and beta-chain of fibrin. J Immunol 166:4177-4784, 2001
  pubmed

• 15) Kinkoch AJ, Tatzer V, Wait R, et al:A novel citrullinated autoantigen, p47cit, in rheumatoid arthritis. Arthritis Rheum 50 (Suppl 9):S522, 2004

• 16) Lopez-Hoyos M, Marquina R, Tamayo E, et al:Defects in the regulation of B cell apoptosis are required for the production of citrullinated peptide autoantibodies in mice. Arthritis Rheum 48:2353-2361, 2003
  pubmed

• 17) Suzuki A, Yamada R, Chang X, et al:Functional haplotyopes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4 are associated with rheumatoid arthritis. Nature Genet 34:395-402, 2003
  pubmed

• 18) Cantaert T, Coucke P, De Rycke L, et al:Rheumatoid arthritis-specific synovial intracellular citrullinated proteins and anti-citrullinated protein antibodies are not associated with functional haplotype PADI4. Arthritis Rheum 50 (Suppl 9):S528, 2004
  pubmed

• 19) Shiozawa S, Hayashi S, Tsukamoto Y, et al:Identification of the gene loci that predispose to rheumatoid arthritis. Int Immunol 10:1891-1895, 1998
  pubmed

• 20) Barton A, Bowes J, Eyre S, et al:A functional haplotype of the PADI4 gene associated with rheumatoid Arthritis in a Japanese population is not associated in United Kingdom Population. Arthritis Rheum 50:1117-1121, 2004

• 21) Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al:Antibodies against citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741-2749, 2003
  pubmed

• 22) Yamane T, Shiozawa K, Tsumiyama K, et al:Autoantibody Activity of IgG rheumatoid factor increases with decreasing levels of gaalactosylation and sialylation. J Biochem (Tokyo) 128:621-628, 2000

• 23) Matsumoto A, Shikata K, Takeuchi F, et al:Autoantibody Activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. J Biochem (Tokyo) 128:621-628, 2000
  pubmed

• 24) Kuroki A, Kuroda Y, Kikuchi S, et al:Level of galactosylation determines cryoglobulin activity of murine IgG3 monoclonal rheumatoid factor. Blood 99:2922-2928, 2002
  pubmed

• 25) 當間重人, 松井利浩:関節リウマチにおける抗CCP抗体測定の臨床的有用性. 自己抗体と自己免疫2004 (山本一彦ほか編), pp11-21, 株式会社医学生物学研究所, 2004

• 26) Young A, Sumar N, Bodman K, et al:An aid to differential diagnosis in early synovitis. Arthritis Rheum 34:1425-1429, 1991
  pubmed

• 27) Blass S, Union A, Raymackers J, et al:The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum 44:761-771, 2001

• 28) Bodman-Smith MD, Corrigall VM, Berglin E, et al:Antibody response to the human stress protein BiP in rheumatoid arthritis. Rheumatology 43:1283-1287, 2004

• 29) Corrigan VM, Bodman-Smith MD, Brunst M, et al:Inhibition of antigen-presenting cell function and stimulation of human peripheral blood mononuclear cells to express an anti-inflammatory cytokine profile by the stress protein BiP:relevance to the treatment of inflammatory arthritis. Arthritis Rheum 50:1164-1171, 2004

• 30) Bodman-Smith MD, Corrigall VM, Kemeny DM, et al:BiP, a putative autoantigen in rheumatoid arthritis, sitmulates IL-10-producing CD8-positive T cells from normal individuals. Rheumatology 42:637-644, 2003

• 31) Corrigan VM, Bodman-Smith MD, Fife MS, et al:The human endoplasmic reticulum molecular chaperone BiP is autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol 166:1492-1498, 2001

• 32) Panayi GS, Brownlie RJ, Corrigall VM, et al:The immunotherapy of collagen-induced arthritis by the stress protein BiP. Arthritis Rheum 50 (Suppl 9):S548, 2004

• 33) Murata M, Miura Y, Hashiramoto A, et al:Heat shock protein 90 (HSP90) is required for increased DNA binding activity of activator protein-1 (AP-1), a heterodimer of Fos/JunD, in rheumatoid synovial cells under inflammatory stimuli. Submitted for publication

• 34) Hashiramoto A, Miura Y, Murata M, et al:Geldanamycin induces apoptosis in rheumatoid synovial cells by down-regulating MAPK and PI3-K pathway. Arthritis Rheum 50 (Suppl 9):S566, 2004

• 35) Rahman A, Hiepe F:Anti-DNA antibodies:overview of assays and clinical correlations. Lupus 11:770-773, 2002
  pubmed

• 36) Walport MJ:Complement. N Engl J Med 344:1140-1144, 2001
  pubmed

• 37) Min DJ, Kim SJ, Park SH, et al:Anti-nucleosome antibody;significance in lupus patients lacking anti-doublestranded DNA antibody. Clin Exp Rheumatol 20:13-13, 2002

• 38) Bruns A, Blass S, Hausdorf G, et al:Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 43:2307-2315, 2000

• 39) Simon JA, Cabiedes J, Ortiz E, et al:Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology 43:220-224, 2004
  pubmed

• 40) Amoura Z, Koutouzov S, Chabre H, et al:Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases. Arthritis Rheum 43:76-84, 2000

• 41) Hadj Hmida YB, Schmit P, Gilson G, et al:Failure to detect antinucleosome antibodies in scleroderma:comment on the article by Amoura et al. Arthritis Rheum 46:280-281, 2002

• 42) Suer W, Dahnrich C, Schlumberger W, et al:Autoantibodies in SLE but not in scleroderma react with prote stripped nucleosomes. J Autoimmun 22:325-334, 2004
  pubmed

• 43) Cortes-Hernandez J, Ordi-Ros J, Labrador M, et al:Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. Am J Med 116:165-173, 2004
  pubmed

• 44) Benucci M, Gobbi FL, Del Rosso A, et al:Disease activity and antinucleosome antibodies in systemic lupus erythematosus. Scand J Rheumatol 32:42-45, 2003
  pubmed

• 45) Ulbricht KU, Schmidt RE, Witte T:Antibodies against alpha-fodrin in Sjogren's syndrome. Autoimmun Rev 2:109-113, 2003
  pubmed

• 46) Haneji N, Nakamura T, Takio K, et al:Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren's syndrome. Science 276:604-607, 1997
  pubmed

• 47) Maeno N, Takei S, Imanaka H, et al:Anti-alpha-fodrin antibodies in Sjogren's syndrome in children. J Rheumatol 28:860-864, 2001

• 48) Normark G, Rorsman F, Ronnblom L, et al:Autoantibodies to alpha-fodrin in primary Sjogren's syndrome and SLE detected by an in vitro transcription and translation assay. Clin Exp Rheumatol 21:49-56, 2003

• 49) Watanabe T, Tsuchida T, Kanda N, et al:Anti-alpha-fodrin antibodies in Sjogren's syndrome and lupus erythematosus. Arch Dermatol 135:535-539, 1999
  pubmed

• 50) Kobayashi I, Kawamura N, Okano M, et al. Anti-alpha-fodrin autoantibody is an early diagnostic marker for childhood primary Sjogren's syndrome. J Rheumatol 28:363-365, 2001
  pubmed

• 51) Maruyama T, Saito I, Hayashi Y, et al:Molecular analysis of the human autoantibody response to alpha-fodrin in Sjogren's syndrorne reveals novel apoptosis-induced specificity. Am J Pathol 165:53-61, 2004

• 52) Kuwana M, Okano T, Ogawa Y, et al:Autoantibodies to the amino-terminal fragment of beta-fodrin expressed in glandular epithelial cells in patients with Sjogren's syndrome. J Immunol 167:5449-5456, 2001

• 53) Spitzenberger F, Pietropaolo S, Verkade P, et al:Islet cell autoantigen of 69 kDa is an arfaptin-related protein associated with the Golgi complex of insulinoma INS-1 cells. J Biol Chem 278:26166-26173, 2003

• 54) Winer S, Astsaturov I, Cheung R, et al:Primary Sjogren's syndrome and deficiency of ICA69. Lancet 360:1063-1069, 2002
  pubmed

• 55) Kouskoff V, Korganow AS, Duchatelle V, et al:Organ-specific disease provoked by systemic autoimmunity. Cell 87:811-822, 1996
  pubmed

• 56) Matsumoto I, Staub A, Benoist C, et al:Arthritis provoked by linked T and B cell recognition of a glycoprotein enzyme. Science 286:1732-1735, 1999

• 57) Muraki Y, Matsumoto I, Chino Y, et al:Glucose-6-phosphate isomerase variants play a key role in the generation of anti-GPI antibodies:possible mechanism of autoantibody production. Biochem Biophys Res Commun 323:518-522, 2004
  pubmed

• 58) Schaller M, Burton DR, Ditzel HJ:Autoantibodies to GPI in rheumatoid arthritis:linkage between animal model and human disease. Nat Immunol 2:746-753, 2001
  pubmed

• 59) Matsumoto I, Lee DM, Goldbach-Mansky R, et al:Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum 48:944-954, 2003

• 60) Van Gaalen FA, Toes RE, Ditzel HJ, et al:Association of autoantibodies to glucose-6 phosphate isomerase with extraarticular complications in rheumatoid arthritis. Arthritis Rheum 50:395-399, 2004
  pubmed

• 61) Jouen F, Vittecoq O, Leguillou F, et al:Diagnostic and prognostic values of anti glucose-6-phosphate isomerase antibodies in community-recruited patients with very early arthritis. Clin Exp Immunol 137:606-611, 2004
  pubmed

• 62) Herve CA, Wait R, Venables PJ:Glucose-6-phosphate isomerase is not a specific autoantigen in rheumatoid arthritis. Rheumatology 42:986-988, 2003

• 63) Van Venrooij WJ, Hazes JM, Visser H:Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 60:383-388, 2004

• 64) Vasishta A:Diagnosing early-onset rheumatoid arthritis:the role of anti-CCP antibodies. Am Clin Lab 21:34-36, 2002
  pubmed

• 65) Pinheiro GC, Scheinberg MA, Aparecida-da Silva M, et al:Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arhtiritis. Ann Intern Med 139:234-235, 2003

• 66) Suzuki K, Sawada T, Murakami A, et al:High diagnositic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 32:197-204, 2003

• 67) Dubucquoi S, Solau-Gervais E, Lefranc D, et al:Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 63:415-419, 2004
  pubmed

• 68) Van Venrooij WJ, Vossenaar ER, Zendman AJW:CCP2:a specific and sensitive test for the detection of (early) rheumatoid arthritis. 山本一彦ほか編:自己抗体と自己免疫2004. pp57-67, 株式会社医学生物学研究所, 2004

P.149 掲載の参考文献

• 1) Rechtschaffen A, Kales A, editors:A manual of standardized terrninology, techniques, and scoring system for sleep stages of human subjects. USDepartment of Health, Education and Welfare, Public Health Service. 1968

• 2) Borbely A:Secrets of sleep. pp25-27, London, Penguin Books, 1986

• 3) The American Sleep Disorders Association Atlas Task Force:EEG arousals. scoring rules and examples. Sleep 15:174-184, 1992

• 4) Aldrich MS, Jahnke B:Diagnostic value of video-EEG polysomnography. Neurology 41:1060-1066, 1991
  pubmed

• 5) Agnew HW, Webb WB, Williams RL:The first night effect:an EEG study of sleep. Psychophysiology 2:263-266, 1966
  pubmed

• 6) Riley TL, Peterson H:Sleep studies in the subject's home. Clin Electroencephalogr 14:96101, 1983

• 7) American Academy of Sleep Medicine Accreditation Committee:Standards for accreditation of a sleep disorder center. March 2002, revised edition, Available from American Academy of Sleep Medicine, Rochester, MN, www.aasmnet.org

• 8) Hauri PJ, Olmstead EM:Reverse first night effect in somnia. Skeep 12:97-105, 1989

• 9) Dijk DJ, Duffy JF, Riel E, et al:Ageing and the circadian and homeostatic regulation of human sleep during. forced desynchrony of rest, melatonin and temperature rhythms. J Physiol 516:611-627, 1999
  pubmed

• 10) Hirishkowitz M, Moore CA, Hamilton CR, et al:Polysomnography of adults and elderly:Sleep architecture, respiration, and leg movement. J Clin Neurophysiol 9:56-62, 1992

• 11) Mathur H, Douglas NJ:Frequency of EEG arousals from nocturnal sleep in normal subject. Sleep 18:330-333, 1995

• 12) Tachibana N, Shinde A, Ikeda A, et al:Supplementary motor area seizure rembling sleep disorder. Sleep 19:811-816, 1996

• 13) Loube DI, Gay PC, Strohl KP, et al:Indications for positive airway pressure treatment for adult obstructive sleep apenea patients:a consensus statement. Chest 115:863-866, 1999

• 14) Tachibana N, Ayas NT, White DP:Japanese versus USA clinical services in sleep medicine. Sleep Biol Rhythm 1:215-220, 2003

• 15) 清水徹男:不眠. 綜合臨牀 52:2961-2966, 2003
  Medical*Online

• 16) 立花直子:周期性四肢運動異常症. 別冊日本臨床 領域別症候群シリーズ 39, 精神医学症候群II:79-82, 2003

• 17) 足立浩祥:睡眠歴のとり方と質問紙の利用方法. 綜合臨牀 52:2944-2952, 2003
  Medical*Online

• 18) 立花直子:一般医にどこまで診断・検査・治療が可能か? 綜合臨牀52:3001-3007, 2003

• 19) www.ama-assn.org/ama/pub/category/3113.html

• 20) Stepanski EJ, Wyatt K:Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 7:215-225, 2003

• 21) Hauri P:Current concepts. the sleep disorders, The Upjohn Company, Kalamazoo, Michigan, 1977

治療と副作用

P.157 掲載の参考文献

• 1) Plant MJ, Jones PW, Saklatvala J, et al:Patterns of radiological progression in early rheumatoid arthritis:results of an 8 year prospective study. J Rheumatol 25:417-426, 1998
  pubmed

• 2) 村田紀和, 前田 晃:早期RAの手・足の変形予防に対する長期臨床研究 (第7報). 昭和63年度特定疾患調査研究結果報告書. 骨-47〜骨-51, 1989

• 3) Schumacher HR, Habre W, Meador R, et al:Predictive factors in early arthritis:Long-term follow-up. Sem Arthritis Rheum 33:264-272, 2004

• 4) Young A, Dixey J, Kulinskaya E, et al:Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 61:335-340, 2002
  pubmed

• 5) 村田紀和, 前田 晃, 小松原良雄:早期慢性関節リウマチの予後-第2報-. 第32回日本リウマチ学会総会発表

• 6) Strand V, Cohen S, Schiff M, et al:Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 59:2542-2550, 1999

• 7) Emery P, Breedveld FC, Lemmel EM, et al:A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatol (Oxford) 39:655-665, 2000

• 8) Smollen JS, Kalden JR, Scott DL, et al:Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis:a double-blind, randomised, multicentre trial. European Leflunomide Study Group Lancet 353:259-266, 1999

• 9) Larsen A, Kvien TK, Schattenkirchner M, et al:Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 30:135-142, 2001

• 10) Strand V, Sharp JT:Radiographic date from recent randomized controlled trials in rheumatoid arthritis. Arthritis Rheum 48:21-34, 2003

• 11) Hayem G, Ballard-Doireau M, Meyer O:Facteurs pronostiques de la polyarthrite rhumatoide debutante. In:L'Actualite Rhumatologique 2003 (Eds:Kahn MF, et al), pp40-53, Paris, Elsevier, 2003

• 12) Drossaers-Bakker KW, Zwinderman AH, Vlieland TP, et al:Long-term outcome in rheumatoid arthritis:a simple algolithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year follwup. Arthritis Rheum 47:383-390, 2002

• 13) Landewe RB, Boers M, Verhoeven AC, et al:COBRA combination therapy in patients with early rheumatoid arthritis:long-term structural benefits of a brief intervention. Arthritis Rheum 46:347-356, 2002
  pubmed

• 14) Bukhari M, Lunt M, Harrison BJ, et al:Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis:results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 46:906-912, 2002
  pubmed

• 15) Combe B, Dougados M, Goupille P, et al:Prognostic factors for radiographic damage in early rheumatoid arthritis:a multiparameter prospedctive study. Atrhritis Rheum 44:1736-1743, 2001

• 16) Garnero P, Lndewe R, Boers M, et al:Association of baseline levels of markers of bone and cartilage degrdation with long-term progression of joint damage in patients with early rheumatoid arthritis. The COBRA study. Arthritis Rheum 46:2847-2856, 2002

• 17) Vencovsky J, Machacek S, Sedova L, et al:Auto antibodies can be prognostic markers of an erosive disease in eraly rheumatoid arthritis. Ann Rheum Dis 62:427-430, 2003

• 18) Meyer O, Labarre C, Dougados M, et al:Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120-126, 2003
  pubmed

• 19) Wakitani S, Murata N, Toda Y, et al:The relationship between HLA-DRBI alleles and disease subsets ofrheumatoid arthritis in japanese. Br J Rheumatol 36:630-636, 1997

• 20) Wagner U, Kaltenhauser S, Pierer M, et al:Prospective analysis of the impact of HLA-DR and-DQ on joint destruction in recent-onset rheumatoid arthritis. Rheumatol 42:553-562, 2003

• 21) 山中 寿:検査・診断法の進歩 血清MMP-3 (matrix metalloproteinase-3). 日本臨床60:2325, 2002

• 22) Berglin E, Lorentzon R, Nordmark L, et al:Predictors of radiological progression and changes in hand bone density in early rheumatoid arthritis. Rheumatol 42:268-275, 2003

• 23) Choi HK, Heman MA, Seeger JD, et al:Methotrexate and mortality in patients with rheumatoid arthritis:a prospective study. Lancet 359:1173-1177, 2002

P.169 掲載の参考文献

• 1) 住田孝之:シェーグレン症候群発症の分子機構-T細胞と対応抗原-. リウマチ42:769-776, 2002

• 2) 高柳一成編:細胞膜の受容体, pp72. 東京, 南山堂. 1998

• 3) 市川陽一, 柏崎禎夫, 原まさ子ら:シェーグレン症候群の口腔乾燥症に対するSNI-2011の長期投与試験. 診療と新薬38:369-391, 2001

• 4) Petrone D, Condemi JJ, Fife R, et al:Adouble-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patient with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46:748-754, 2002

• 5) 山田秀裕:セビメリンの臨床知見から学ぶSjogren症候群の多彩な病態形成機序. 医薬ジャーナル39:1591-1596, 2003

• 6) Robinson CP, Brayer J, Yamachika S, et al:Transfer of human serum IgG to nonobese diabetic Igmu null mouse reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci USA 95:7538-7543, 1998
  pubmed

• 7) Steinfeld SD & Appelboom T:Treatment with infliximab restores normal aquaporin 5 distribution in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 46:2249-2250, 2002
  pubmed

• 8) Wall GC, Magarity ML & Jundt JW:Pharmacotherapy of xerostomia in primary Sjogren's syndrome. Pharmacotherapy 22:621-629, 2002
  pubmed

• 9) Vivino F, Al-Hashimi I, Khan Z, et al:Adouble-blind, fixed dose, placebo-controlled study of oral pilocarpine HCL tablets for the treatment of symptoms associated with dry mouth due to Sjogren's syndrome. Arthritis Rheum 40:9 (Supp):S202, 1997

• 10) Nusair S & Rubinow A:The use of oral pilocarpine in xerostomia and Sjogren's syndrome. Semin Arthritis Rheu 28:360-367, 1999

• 11) Shiozawa S & Shiozawa K:Role of endogenous α-interferon in the host's protection against virus infection and autoimmunity. Int J Immunotherapy V:1-8, 1989

• 12) Shiozawa S, Shiozawa K, Shimizu S, et al:Immunoreactive circulating alpha-interferon is low in Sjogren's syndrome. Br J Rheumatol 29:50-52, 1990
  pubmed

• 13) Shiozawa S, Shiozawa K, Kita M, et al:A preliminary study on the effect of alpha-interferon treatment on the joint inflammation and serum calcium in rheumatoid arthritis. Br J Rheumatol 31:405-408, 1992

• 14) Shiozawa S, Cummins JM & Fox PC:Opening the flood gates. Interferon-α treatment for Sjogren's syndrome. BioDrugs 13:305-311, 2000

• 15) 塩沢和子:シェーグレン症候群1993. リウマチ病セミナーV (七川歓次監修) pp10-20, 大阪, 永井書店, 1994

• 16) Ship JA, Fox PC, Michalek JE, et al:Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route:phase II clinical trial. J Interferon Cytokine Res 19:943-951, 1999

• 17) Cummins MJ, Papas A, Kammer GM, et al:Treatment of primary Sjogren's syndrome with low-dose human interferon alpha administered by the oromucosal route:combined phase II results. Arthritis Rheum 49:585-593, 2003

• 18) Steinfeld SD, Cogan E, King LS, et al:Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjogren's syndrome patients. Lab Invest 81:143-148, 2001

• 19) Beroukas D, Hiscock J, Jonsson R, et al:Subcellular distribution of aquaporin 5 in salivary glands in primary Sjogren's syndrome. Lancet 358:1875-1876, 2001
  pubmed

• 20) Beroukas D, Hiscock J, Gannon BJ, et al:Selective downregulation of aquaporin-1 in salivary glands in primary Sjogren's syndrome. Lab Invest 82:1547-1552, 2002
  pubmed

• 21) Steinfeld SD, Demols P, Salmon I, et al:Infliximab in patients with primary Sjogren's syndrome. a pilot study. Arthritis Rheum 44:2371-2375, 2001
  pubmed

• 22) Steinfeld SD, Demols P & Appelboom T:Infliximab in primary Sjogren's syndrome. Arthritis Rheum 46:3301-3303, 2002
  pubmed

• 23) Mariette X, Ravaud P, Steinfeld S, et al:Inefficacy of infliximab in primary Sjogren's syndrome:results of the randomized, controlled trial of Remicade in primary Sjogren's syndrome (TRIPSS). Arthritis Rheum 50:1270-1276, 2004
  pubmed

• 24) Zandbelt MM, de Wilde P, van Damme P, et al:Etanercept in the treatment of patients with primary Sjogren's syndrome. a pilot study. J Rheumatol 31:96-101, 2004
  pubmed

• 25) Somer BG, Tsai DE, Downs L, et al:Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 49:394-398, 2003
  pubmed

• 26) Mariette X, Roux S, Zhang J, et al:The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 62:168-171, 2003
  pubmed

• 27) Tishler M, Yaron I, Shirazi I, et al:Hydroxychloroquine treatment for primary Sjogren's syndrome its effect on salivary and serum inflammatory markers. Ann Rheum Dis 58:253-256, 1999
  pubmed

• 28) Fox RI, Dixon R, Guarrasi V, et al:Treatment of primary Sjogren's syndrome with hydroxychloroquine. a retrospective, open-label study. Lupus Jun 5:S31-36, 1996
  pubmed

• 29) Kruize AA, Hene RJ, Kallenberg CG, et al:Hydropxychloroquine treatment for primary Sjogren's syndrome. a two year double blind crossover trial. Ann Rheurn Dis 52:360-364, 1993
  pubmed

• 30) Skopouli FN, Jagiello P, Tsifetaki N, et al:Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol 14:555-558, 1996
  pubmed

• 31) Pflugfelder SC:Anti-inflammatory therapy for dry eye. Am J Ophthalmol 137:337-342, 2004
  pubmed

• 32) Stevenson D, Tauber J & Reis BL:Efficacy and safety of cyclosporin A emulsion in the treatment of moderate-to-severe dry eye disease:a dose-ranging:randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 107:967-974, 2000
  pubmed

• 33) Marsh P & Pflugfelder SC:Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 106:811-816, 1999
  pubmed

• 34) Haneji N, Nakamura T, Takio K, et al:Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren's syndrome. Science 276:604-607, 1997
  pubmed

• 35) Ruffatti A, Ostuni P, Grypiotis P, et al:Sensitivity and specificity for primary Sjogren's syndrome of IgA and IgG anti-alpha-fodrin antibodies detected by ELISA. J Rheumatol 31:504-507, 2004
  pubmed

• 36) 塩沢俊一:新しい自己抗体. リウマチ病セミナーXV (七川歓次監修) pp129-141, 大阪, 永井書店, 2004

• 37) Saegusa K, Ishimaru N, Yanagi K, et al:Prevention and induction of autoimmune exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjogren's syndrome. J Immunol 169:1050-1057, 2002
  pubmed

• 38) Kuwana M, Okano T, Ogawa Y, et al:Autoantibodies to the amino-terminal fragment of beta-fodrin expressed in glandular epithelial cells in patients with Sjogren's syndrome. J Immunol 167:5449-5456, 2001

• 39) Bolstad AI, Eiken HG, Rosenlund B, et al:Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4 and programmed cell death 1 in primary Sjogren's syndrome. Arthritis Rheum 48:174-185, 2003
  pubmed

P.175 掲載の参考文献

• 1) Nishimoto N, Kishimoto T, Yoshizaki K:Anti-interleukin 6 antibody treatment in rheumatic disease. Ann Rheum Dis 59:21-27, 2000
  pubmed

• 2) Sato K, Tsuchiya M, Saldanha J, et al:Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53:851-856, 1993
  pubmed

• 3) Nishimoto N, Yoshizaki K, Maeda K, et al:Toxicity, pharmacokinetics and dose finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody, MRA, in rheumatoid arthritis-Phase I/II clinical study. J Rheumatol 30:1426-1435, 2003
  pubmed

• 4) Choy EH, Isenberg DA, Garrood T, et al:Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin-6 receptor monoclonal antibody. Arthritis Rheum 46:3143-3150, 2002
  pubmed

• 5) Nishimoto N, Yoshizaki K, Miyasaka N, et al:Treatment of rheumatoid arthritis with humanized anti-interleukin6 receptor antibody. Arthritis Rheum 50:1761-1769, 2004.
  pubmed

• 6) Maini RN, Taylor PC, Pavelka K, et al:Efficacy of IL-6 receptor antagonist MRA in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). Arthritis Rheum 48:S652:1704, 2003

P.183 掲載の参考文献

• 1) Dormandy JA & Rutherford RB:Management of peripheral arterial disease (PAD). TASC Working Group. J Vasc Surg 31:Sl-S296, 2000

• 2) Baffour R, et al:Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia:dose-response effect of basic fibroblast growth factor. J Vasc Surg 16:181-191, 1992

• 3) Pu LQ, et al:Enhanced revascularization of the ischemia limb by means of angiogenic therapy. Circulation 88:208-215, 1993

• 4) Yanagisawa-Miwa A, et al:Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257:1401-1403, 1992
  pubmed

• 5) Takeshita S, et al:Therapeutic angiogenesis:a single intraarterial bolus of vascular endotherial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93:662-670, 1994

• 6) Bauters C, et al:Site-specific therapeutic angiogenesis following systemic administration of vascular endotherial growth factor. J Vasc Sur 21:314-325, 1995

• 7) Baumgartner I, Pieczek A, Manor O, et al:Constitutive expression of phVEGF after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114-1123, 1998

• 8) Losordo DW, et al:Gene therapy for myocardial angiogenesis:Initial clinical results with direct myocardial injection of phVEGF as sole therapy for myocardial ischemia. Circulation 98:2800-2804, 1998

• 9) Taniyama Y, et al:Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hind limb ischemia models:preclinical study for treatment of peripheral arterial disease. Gene Therapy
  pubmed

• 10) Aoki M, et al:Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infracted myocardium:up-regultion of essential transcription factor for angiogenesis, ets. Gene Therapy 7:417-427, 2000

P.192 掲載の参考文献

• 1) Tanaka T, Hanyu T, Takahashi HE:Bone loss in iliac biopsies. A comparison between rheumatoid arthritis and postmenopausal osteoporosis using a histomorphometric suty. Acta Medica et Biologica 50:43-52, 2002

• 2) Hanyu T, Arai K, Takahashi HE:Structural mechanisms of bone loss in iliac biopsies. Comparison between rheumatoid arthritis and postmenopausal osteoporosis. Rheumatol Int 18:193-200, 1999
  pubmed

• 3) Kleerekoper M, Villanueva AR, Stanciu J, et al:The role of three-demensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int 37:594-597, 1985

• 4) Recommendations for the prevention and treatment of glucocoticoid-induced osteoporosis:American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 39:1791-1801, 1996

• 5) Adachi AD, Bensen WG, Brown J, et al:Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387, 1997
  pubmed

• 6) Saag KG, Emkey R, Schintzer TJ, et al:Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299, 1998

• 7) Adachi AD, Saag KG, Delmas P, et al:Two-year effect of alendronate on bone mineral density and vertebral fracture in patient receiving glucocorticoids. Arthritis Rheum 44:202-211, 2001

• 8) Wallach S, Cohen S, Reid DM, et al:Effects of risedronate treatment on done density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277-285, 2000
  pubmed

• 9) Recommendations for the prevention and treatment of glucocoticoid-induced osteoporosis:2001 update, American College of Rheumatology Ad Hoc Committee on Glucocoticoid-induced Osteoporosis. Arthritis Rheum 44:1496-1503, 2001

• 10) Lindsay R, Silverman SL, Cooper C, et al:Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323, 2001
  pubmed

• 11) Fujita T, Inoue T, Morii H, et al:Effect of an intermitted weekly dose of human parathyroid hormone (1-34) on osteoporosis. A randomized double-masked prospective study using three dose levels. Osteoporosis Int 9:290-306, 1999

• 12) Neer RM, Arnaud CD, Zanchetta JR, et al:Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J med 344:1434-1441, 2001
  pubmed

• 13) Lane NE, Sanchez S, Modin GW, et al:Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis. Results of a randomized controlled clinical trial. J Bone Miner Res 15:944-951, 2000
  pubmed

P.199 掲載の参考文献

• 1) 有沢紀子, 蓮沼智子, 鈴木真奈絵ら:臨床薬理試験におけるプラセボ投与時の白覚症状発現に関する検討-過去13年間における集計-. 臨床薬理34, 361-362, 2003

• 2) 中野重行:プラセボ反応. 臨床薬理学第2版 (日本臨床薬理学会編), pp97-100, 2003

• 3) Beecher HK:The powerful placebo. JAMA159:1602-1606, 1955
  pubmed

• 4) 横田慎一, 熊谷雄治:臨床第一 相試験におけるプラセボ投与時の自覚症状発現に関する検討. 薬剤疫学 1, 67-68, 1996

• 5) 有田悦子, 熊谷雄治t横田慎一:臨床第1相試験におけるプラセボ投与時の自覚症状発現に関する検討-精 神科系薬剤を中心に-. 臨床薬理31, 165-166, 2000

• 6) Smolen JS, Kalden JR, Scott DL, et al:Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis. a double-blind, randomised, multicentre trial. THE LANCET 353:259-266, 1999

• 7) Strand V, Cohen S, Schiff M, et al:Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate. ARCH INTERN MED 159:2542-2550, 1999
  pubmed

P.209 掲載の参考文献

• 1) Townes AS, Sowa JM, Shulman LE:Controlled trial of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum 19:563-573, 1976

• 2) Chabner BA, Allegra CJ, Curt GA, et al:Antineoplastic agents. In:Goodman & Gilman's the Pharmacological Basis of Therapeutics. 9th ed (Ed:Hardman JG, Limbird LE), pp1233, New York, McGraw-Hill, 1996

• 3) Cooperative clinics committee of the American Rheumatism Association:A controlled trial of cyclophosphamide in rheumatoid arthritis. N Engl J Med 283:883-889, 1970

• 4) Renier JC, Deshayes P, Besson J, et al:Traitement de la polyarthrite rheumato de par le by chlorambucil. propos de 48 obsevations. Presse Med 75:2527-2530, 1967

• 5) Fosdick WM, Parsons JL, Hill DF:Long-term cyclophosphamide therapy in rheumatoid arthritis, Arthritis Rheum 11:151-161, 1968
  pubmed

• 6) Moore MJ:Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20:194-208, 1991
  pubmed

• 7) Garcia ST, McQuillan A, Panasci L:Correlation between the cytotoxicity of melphalan and DNA crosslinks as detected by the ethidium bromide fluorescence assay in the F1 variant of B16 melanoma cells. Biochem Pharmacol 37:3189-3192, 1988
  pubmed

• 8) Stein CM:Immunoregulatory drugs. In:Kelley's Textbook of Rheumatology. 6th ed (Ed:Ruddy S, Harris Jr ED, Sledge CB), pp879, Philadelphia, WB Saunders, 2001

• 9) Hurd ER, Giuliano VJ:The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases. Arthritis Rheum 18:67-75, 1975

• 10) Horwitz DA:Selective depletion of Ig-bearing lymphocytes by cyclophosphamide in rheumatoid arthritis and systemic lupus erythematosus. Guidelines for dosage. Arthritis Rheum 17:363-374, 1974
  pubmed

• 11) Lacki JK, Schochat T, Sobieska M, et al:Immunological studies in patients with rheumatoid arthritis treated with methotrexate or cyclophosphamide. Z Rheumatol 53:76-78, 1994
  pubmed

• 12) Hurd ER, Ziff M, et al:Parameters of improvement in patients with rheumatoid arthritis treated with cyclophosphamide. Arthritis Rheum 17:72-80, 1974
  pubmed

• 13) Stockman GD, Heim LR, South MA, et al:Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol 110:277-282, 1973

• 14) Misra RR, Bloom SE, et al:Roles of dosage, pharmacokinetics and cellular sensitivity to damage in the selective toxicity of cyclophosphamide towards B and T cells in development. Toxicology 66:239-256, 1991

• 15) Misra RR, Lorr NA, Bloom SE, et al:Cyclophosphamide metabolism in the primary immune organs of the chick:assays of drug activation, P450 expression and aldehyde dehydrogenase. Arch Toxicol 65:32-38, 1991
  pubmed

• 16) Yuan ZM, Smith PB, Brundrett RB, et al:Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry. Drug Metab Dispos 19:625-629, 1991

• 17) Kastan MB, Schlaffer E, Russo JE, et al:Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 75:1947-1950, 1990
  pubmed

• 18) Wilmer JL, Colvin OM, Bloom SE, et al:Cytogenetic mechanisms in the selective toxicity of cyclophosphamide analogs and metabolites towards avian embryonic B lymphocytes in vivo. Mutat Res 268:115-130, 1992
  pubmed

• 19) EMPIRE Rheumatism Council:multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis;results of three years' treatment. Ann Rheum Dis 16:277-289, 1957

• 20) Empire Rheumatism Council:Gold therapy in rheumatoid arthritis. A multi-centre controlled trial. Ann Rheum Dis 19:95-119, 1960

• 21) Lidsky MD, Sharp JT, Billings S, et al:Double-blind study of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum 16:148-153, 1973
  pubmed

• 22) Williams HJ, Reading JC, Ward JR, et al:Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 23:521-527, 1980
  pubmed

• 23) Sawitzke M, Cannon GW:Cytotoxic drugs. In Arthritis and allied conditions, 14th ed (Ed:Koopman WJ), pp794, Philadelphia, Lippincott Williams & Wilkins, 2001

• 24) Baker GL, Kahl LE, Zee BC, et al:Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 83:1-9, 1987
  pubmed

• 25) Radis CD, Kahl LE, Baker GL, et al:Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 38:1120-1127, 1995
  pubmed

• 26) Keysser G, Keysser C, Keysser M:Treatment of refractory rheumatoid arthritis with low-dose cyclophosphamide. Long-term follow-up of 108 patients. Z Rheumatol 57:101-107, 1998
  pubmed

• 27) Nicol D:Cyclophosphamide and the urinary tract. Intern Med J 32:199-201, 2002
  pubmed

• 28) Arnold MH, Janssen B, Schrieber L, et al:Prospective pilot study of intravenous pulse cyclophosphamide therapy for refractory rheumatoid arthritis. Arthritis Rheum 32:933-934, 1989
  pubmed

• 29) Maeyaert B, Westhovens R, Dequeker J:Cyclophosphamide pulse in combination therapy for refractory rheumatoid arthritis. J Rheumatol 23:197-198, 1996
  pubmed

• 30) De Vita S, Zaja F, Sacco S, et al:Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis:evidence for a pathogenetic role of B cells. Arthritis Rheum 46:2029-2033, 2002
  pubmed

• 31) Leandro MJ, Edwards JC, Cambridge G:Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883-888, 2002
  pubmed

P.218 掲載の参考文献

• 1) Hench PS:The reversibility of certain rheumatic and non-rheumatic conditions by the use of cortisone or of the pituitary adrenocorticotropic hormone. Physiology or Medicine, pp311-341, Amsterdam, Nobel Lectures, 1942-1962, 1964

• 2) Fujita K, Kasayama S, Hashimoto J, et al:Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women. J Bone Miner Res 16:782-787, 2001

• 3) Hubbard RB, Smith CJP, Smeeth L, et al:Inhaled corticosteroids and hip fracture. A population-based control study. Am J Respir Crit Care Med 166:1563-1566, 2002
  pubmed

• 4) Truss M, Beato M:Steroid hormone receptors:interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 14:459-479, 1993
  pubmed

• 5) Akira S, Hirano T, Taga T, et al:Biology of multifunctional cytokines:IL-6 and related molecules (IL1 and TNF). FASEB J 4:2860-2867, 1990

• 6) De Bosscher K, Berghe WV, Vermeulen L, et al:Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery. irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 97:3919-3924, 2000

• 7) Vayssiere BM, Dupont S, Choquart A, et al:Synthetic glucocorticoid that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 11:1245-1255, 1997
  pubmed

• 8) Caulin-Glaser T, Watson CA, Pardi R, et al:Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 98:36-42, 1996

• 9) Otsuki M, Saito H, Xu X, et al:Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 (VCAM-1) expression in human vascular endothelial cells. Arterioscl Thromb Vasc Biol 21:243-248, 2001
  pubmed

• 10) Gille J, Paxton LLL, Lawley TJ, et al:Retinoic acid inhibits the regulated expression of vascular cell adhesion molecule-1 by cultured dermal microvascular endothelial cells. J Clin Invest 99:492-500, 1997

• 11) Marx N, Sukhova GK, Collins T, et al:PPAR α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression human endothelial cells. Circulation 99:3125-3131, 1999

• 12) Xu X, Otsuki M, Saito H, et al:PPARα and GR differentially down-regulate the expression of nuclear factor-κ B-responsive genes in vascular endothelial cells. Endocrinology 142:3332-3339, 2001

• 13) Wada K, Nakajima A, Blumberg RS:PPARγ and inflammatory bowel disease. a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med 7:329-331, 2001

P.223 掲載の参考文献

• 1) Sampaio EP, Sarno EN, Galilly R, et al:Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 173:699-703, 1991
  pubmed

• 2) Keifer JA, Guttridge DC, Ashburner BP, et al:Inhibition of NF-kB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem 276:22382-7, 2001

• 3) D'Amato RJ, Loughnan MS, Flynn E, et al:Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085, 1994
  pubmed

• 4) Keesal IN, Wasserman MJ, Bookman A, et al:Thalidomide in the treatment of refractory rheumatoid arthritis. J Rheumatol 26:2344-2347, 1999
  pubmed

• 5) Scoville CD:Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 19:360-361, 2001

• 6) Breban M, Gourbert B, Amor B, et al:Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 42:580-581, 1999

• 7) Haung F, Gu J, Zhao W, et al:One-year open label trial of thalidomide in ankylosing spondylitis. Arthritis Care & Research 47:249-254, 2002

• 8) Sato EI, Assis LS, Lourenzi VP, et al:Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras 44:289-293, 1998
  pubmed

• 9) Gutierrez-Rodriguez O:Thaidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum 27:1118-1121, 1984
  pubmed

• 10) Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O:Treatment of refractory rheumatoid arthritis-the thalidomide experience. J Rheumatol 16:158-163, 1989
  pubmed

P.228 掲載の参考文献

• 1) 木村 敏:医学への主観の導入. 第14回近畿リウマチ病研究会講演集, pp45-48, 2003

• 2) AHマズロー:人間性の心理学-motivation and personality 第13版 (小口忠彦訳), pp89-117, 東京, 産業能率大学出版部, 1971

• 3) Pincus T, Leigh FC:Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. J Chron Dis 38:973-984, 1985

手術

P.244 掲載の参考文献

• 1) 龍順之助, 松野博明:下肢の手術療法. 診断のマニュアルとEBMに基づく治療ガイドライン (厚生労働省研究班), pp120-133, 東京, 日本リウマチ財団, 2004

• 2) 小松原良雄:X線よりみた関節リウマチ患者の関節再建術の必要性. リウマチ病セミナーXIV (七川歓次監 修), pp203-214, 大阪, 永井書店, 2003

• 3) 井上一:リウマチ肘に対する人工関節手術. リウマチ病セミナーXIV (七川歓次監修), pp243-251, 大阪, 永井書店, 2003

• 4) 藤田悟, 政田和洋, 小松原良雄, ら:慢性関節リウマチに対するSaure-kapandji法の改良. 日本手の外科学会雑誌16:911, 1999

• 5) Fujita. S, Masada. K, komatubara. Y, et al:Modified Saure-kapandji operation. Hand Surgery in the next miliennium. 2nd Congress AsianPacific federation of Societies for Surgery of the Hand, pp169-174, 1999

• 6) 石川肇, 松野博明:上肢の手術療法. 診断のマニュアルとEBMに基づく治療ガイドライン (厚生労働省研究班), pp107-119, 東京, 日本リウマチ財団, 2004

P.252 掲載の参考文献

• 1) Doody SG, Freedman L, Waterland JC:Shoulder movements during abduction in the scapular plane. Arch Phys Med Rehabil 51:595-604, 1970
  pubmed

• 2) Friedman RJ:Prospective analysls of total shoulder arthroplasty biomechanics. Am J Orthop 26:265-270, 1997
  pubmed

• 3) Inman VT, Saunders JB, Abbott LC:Observations on the function on the shoulder joint. J Bone Joint Surg 26:1-30, 1944

• 4) Lee DH, Niemann KMW:Bipolar shoulder arthroplasty. Clin Orthop 304:97-107, 1994

• 5) 宮本隆, 菅本一臣, 原田拓ら:MRIによるリウマチ肩の障害進行様式の検討. 肩関節24:199-203, 2000

• 6) Sojbjerg JO, Frich LH, Johannsen HV, et al:Late results of total shoulder replacement in patients with rheumatoid arthritis. Clin Orthop 366:39-45, 1999
  pubmed

• 7) Sperling JW, Cofield RH, Rowland CM:Neer hemiarthroplasty and Neer total shoulder arthroplasty in patients fifty years old or less. J Bone Joint Surg 80-A:464-473, 1998
  pubmed

• 8) Worland RL, Arredondo J:Bipolar shoulder arthroplasty for painful conditions of the shoulder. J Arthroplasty 13:631-637, 1998